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Myocardial circulatory insufficiency, cardiomyocyte necrosis,and apoptosis play important roles in many pathologic con-ditions of the heart. Therapeutic approaches aimed at promot-ing angiogenesis and growing new heart muscle fibers, cur-rently undergoing intensive investigation and early clinicaltrials, therefore hold considerable promise for the future.
Genes encoding angiogenic factors and angiogenic growth factor proteins, such as
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor, are
being delivered to the target tissue to induce growth of new blood vessels. For
myogenesis, various progenitor and stem cells are being assessed as donor cells for
implantation into the ventricular wall of injured hearts. Phase I and II clinical trials
have already been undertaken for myocardial angiogenesis. Clinical studies into
myogenesis have been recently initiated with implantation of autologous skeletal
myoblasts into myocardial scar tissue. Although the results of phase I safety studies
so far are promising, the establishment of efficacy requires rigorous phase II and III
studies yet to come.
Cardiac myogenesis and angiogenesis represents a paradigm shift in our thera-
peutic approach, from substitution to regeneration of irreversibly damaged cardiac
tissues and structures. These new modalities of therapy will not be constrained by
the scarcity of donor organs, immunologic rejection, or the need for mechanical
devices requiring maintenance and replacement. Regenerative medicine and surgery
are in fact in vivo “tissue engineering.” This could be supplemented by in vitro
tissue engineering in which an anatomic structure such as a heart valve could be
fabricated with the use of a patient’s own cells, culturing and growing them in vitro
on appropriate biodegradable scaffolds. Such regenerated tissues and constructs
may not only function normally, but also should be able to grow and remodel.
Yet in the short term this new frontier contains many challenges. Optimal means
of inducing angiogenesis remain elusive, and many questions persist. For example,
the strategy of using genetically engineered cells to deliver angiogenic genes to the
target tissue has been pursued by many investigators. However, would endothelial
cell transplantation per se be useful for angiogenesis, as suggested in an accompa-
nying article by Kim and associates?1 In the presence of appropriate angiogenic
factors, at present there is no evidence of a shortage of endothelial cells for
angiogenesis. These can be derived from local vascular budding (angiogenesis), as
well as from circulating pro-endothelial cells (vasculogenesis), which, as recent
evidence shows, could be recruited from the bone marrow.2 In vitro, endothelial
cells in culture will form tubular capillary structures only in the presence of
angiogenic growth factors. In vivo, reduction in angiogenic factor stimulus during
scar remodeling results in the regression of vascularity with apoptosis of endothelial
cells. Thus, the observation of Kim and colleagues1 that angiogenesis was induced
with endothelial cell transplantation into a scar without increased VEGF expression
is provocative. Perhaps such a finding could be further confirmed in a future study,
if angiogenesis can indeed be induced by endothelial transplantation despite block-
age of VEGF or VEGF receptors.
However, an increase in capillary density does not necessarily lead to better
blood perfusion, unless the capillaries mature and connect with arterial inflow.
Many of the capillaries in the body are not open under basal conditions. The
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magnitude of tissue perfusion is controlled by the arteriolar
tone, and capillaries are recruited to carry blood flow to
meet tissue demands. Thus, increase in blood flow may not
necessarily follow increased capillary density by angiogen-
esis, and coronary blood flow measured ex vivo may not
represent actual blood flow in vivo.
Likewise, in the myoblast implant studies, a number of
perplexing questions also remain. The skeletal myoblasts
transplanted into the ventricular wall of a heart have been
reported to differentiate either into skeletal slow-twitch
muscle fibers3 or transdifferentiate into cardiomyocytes.4 In
one study, it was reported that these myoblasts may express
two different phenotypes, with skeletal muscle phenotype in
the center of a myocardial scar and features of immature
cardiomyocytes at the ischemic border zone.5 Furthermore,
such myoblasts implanted into myocardial scar have been
reported to improve systolic fiber shortening, even though
no syncytial integration of these cells with native myocar-
dial fibers could be recognized because they were sur-
rounded by the fibrous scar tissue.6 This is curious inasmuch
as an anatomic supracellular integration seems a necessary
prerequisite for synchronized contractions of these new
muscle cells during ventricular systole. Clarifying such di-
lemmas should help us in accepting some of the findings
being reported from functional studies.
Recently, cells other than the myoblasts, such as the
adult stem cells in the bone marrow, are being studied as
donor cells for cellular cardiomyoplasty, as they are more
versatile stem cells capable of differentiating into many
phenotypes, including cardiomyocytes, endothelial cells,
and myofibroblasts.7 Attempts are also being made to trans-
fect myoblasts and stem cells with angiogenic genes during
culture before their implantation into the myocardium, in an
effort to achieve both cardiac angiogenesis and myogenesis
simultaneously. There is, however, some evidence that
these cells may spontaneously express angiogenic factors in
vivo and induce angiogenesis while they differentiate, so
that whether in fact preimplant genetic engineering is re-
quired remain to be further examined.
Central to future advancement in this new frontier is to
learn how signals are presented physically and temporally to
cells and how cells integrate multiple signals to generate a
response. With such understanding, we will learn how to
manipulate the microenvironment, both in vitro and in vivo,
so that we can better design tissues and constructs to meet
our therapeutic needs.
References
1. Kim E-J, Li R-K, Weisel RD, Mickle DAG, Jia Z-Q, Tomita S, Sakai
T, Yau TM. Angiogenesis by endothelial cell transplantation. J Thorac
Cardiovasc Surg. 2001;122:963-7.
2. Takahashi T, Kolka C, Masuda H, Chen D, Silver M, Kearney M, et
al. Ischemia and cytokine induced mobilization of bone marrow de-
rived endothelial progenitor cells for neovascularization. Nat Med.
1999;5:434-8.
3. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal
myoblasts transplantation for repair of myocardial necrosis. J Clin
Invest. 1996;98:2512-23.
4. Kao RL, Chin TK, Ganote CE, et al. Satellite cell transplantation to
repair injured myocardium. Card Vasc Regen. 2000;1:31-42.
5. Atkins BZ, Lewis CW, Kraus WE, Hutcheson KA, Glower DD,
Taylor DA. Intracardiac transplantation of immature skeletal myo-
blasts yields two population of striated cells in situ. Ann Thorac Surg.
1999;67:124-9.
6. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC,
Hutcheson KA, et al. Regenerating functional myocardium: improved
performance after skeletal myoblast transplantation. Nat Med. 1998;
4:929-33.
7. Wang J-S, Shum-Tim D, Chedrawy E, Chiu RC-J. The coronary
delivery of marrow stromal cells for myocardial regeneration: patho-
physiologic and therapeutic implications. J Thorac Cardiovasc Surg.
2001;122:699-705.
Editorials Chiu
S56 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
